News

Press release

22 Dec 2020

MDGH receives U.S. FDA clearance of Investigational New Drug Application for dovramilast in leprosy type 2 reaction

Medicines Development for Global Health receives U.S. FDA clearance of Investigational New Drug Application for dovramilast in leprosy type 2 reaction

April 30, 2025

Press release

22 Dec 2020

MDGH submits dovramilast Investigational New Drug Application to U.S. FDA for leprosy type 2 reaction

Medicines Development for Global Health submits an Investigational New Drug Application for dovramilast for the treatment of leprosy type 2 reaction

February 20, 2025

Press release

22 Dec 2020

Medicines Development for Global Health (MDGH) announced today that the U.S. FDA has approved its sNDA for moxidectin for the treatment of river blindness in young children

U.S. FDA expands indication for moxidectin to treat river blindness in children as young as four

February 20, 2025

Press release

22 Dec 2020

Medicines Development for Global Health (MDGH) announced today that the Ghana Health Service has commenced the rollout of moxidectin for the treatment of river blindness (onchocerciasis) in adults and children aged 4 years and older.

Ghana rolls out moxidectin, a new treatment for river blindness

January 28, 2025

Press release

22 Dec 2020

Medicines Development for Global Health (MDGH) announced today that the Ghana Food and Drugs Authority (FDA) approved moxidectin 2 mg oral tables for the treatment of river blindness (onchocerciasis) in adults and children aged 4 years and older.

Ghana becomes first river blindness-endemic country to approve moxidectin

December 5, 2024

Article

22 Dec 2020

Recruitment into Phase 2b clinical trial for scabies complete

October 24, 2024

Article

22 Dec 2020

An update on the progress of our major programs

October 16, 2024

Article

22 Dec 2020

Medicines Development for Global Health receives $16M grant to progress two important global health medicines: moxidectin and dovramilast

June 21, 2024

Article

22 Dec 2020

2022-23 Annual Report

June 18, 2024

Article

22 Dec 2020

Scabies program update

May 14, 2024

Article

22 Dec 2020

Ghanaian Onchocerciasis Expert Committee meeting

May 14, 2024

Article

22 Dec 2020

Medicines Development for Global Health receives US$1M grant for a moxidectin pilot community treatment program

February 12, 2024

Article

22 Dec 2020

Reaching the Last Mile Forum, Dubai, UAE

December 22, 2023

Article

22 Dec 2020

Spotlight on Dr Peya Gaye, Senior Clinical Project Manager, Medicines Development for Global Health

December 21, 2023

Article

22 Dec 2020

Medicines Development for Global Health & Atticus Medical enroll first patient in Phase 2b study of moxidectin in scabies

November 30, 2023

Article

22 Dec 2020

2023 International Conference on Public Health in Africa

November 29, 2023

Article

22 Dec 2020

Medicines Development for Global Health Receives FDA Orphan Drug Designation for Dovramilast to Treat Leprosy Type 2 Reaction

November 3, 2023

Article

22 Dec 2020

American Society for Tropical Medicine and Hygiene Annual Meeting

October 20, 2023

Article

22 Dec 2020

Phase 3b/4 study comparing moxidectin with ivermectin in river blindness is fully enrolled

October 19, 2023

Article

22 Dec 2020

New modelling study suggests potential for moxidectin to accelerate elimination of river blindness in Africa

October 19, 2023

No results found

Please try again.

Press release

Medicines Development for Global Health receives U.S. FDA clearance of Investigational New Drug Application for dovramilast in leprosy type 2 reaction

Press release

Medicines Development for Global Health submits an Investigational New Drug Application for dovramilast for the treatment of leprosy type 2 reaction

Press release

U.S. FDA expands indication for moxidectin to treat river blindness in children as young as four

Press release

Ghana rolls out moxidectin, a new treatment for river blindness

Press release

Ghana becomes first river blindness-endemic country to approve moxidectin

Article

Recruitment into Phase 2b clinical trial for scabies complete

Article

An update on the progress of our major programs

Article

Medicines Development for Global Health receives $16M grant to progress two important global health medicines: moxidectin and dovramilast

Article

2022-23 Annual Report

Article

Scabies program update

Article

Ghanaian Onchocerciasis Expert Committee meeting

Article

Medicines Development for Global Health receives US$1M grant for a moxidectin pilot community treatment program

Article

Reaching the Last Mile Forum, Dubai, UAE

Article

Spotlight on Dr Peya Gaye, Senior Clinical Project Manager, Medicines Development for Global Health

Article

Medicines Development for Global Health & Atticus Medical enroll first patient in Phase 2b study of moxidectin in scabies

Article

2023 International Conference on Public Health in Africa

Article

Medicines Development for Global Health Receives FDA Orphan Drug Designation for Dovramilast to Treat Leprosy Type 2 Reaction

Article

American Society for Tropical Medicine and Hygiene Annual Meeting

Article

Phase 3b/4 study comparing moxidectin with ivermectin in river blindness is fully enrolled

Article

New modelling study suggests potential for moxidectin to accelerate elimination of river blindness in Africa

No results found

Media kit

Stay up to date

Thank you for your interest in Medicines Development for Global Health.